249,812 Shares in Cytek Biosciences, Inc. $CTKB Purchased by Tudor Investment Corp ET AL

Key Points

• Tudor Investment Corp ET AL initiated a new position in Cytek Biosciences (NASDAQ:CTKB), buying 249,812 shares worth about $867,000, representing roughly 0.20% of the company.
• Several other institutions materially increased stakes—Topline Capital now holds 6.94M shares (~$24.1M) and Royce & Associates owns 1.76M shares (~$6.12M)—with institutional ownership at about 69.46%.
• Cytek has a market cap of about $590.7M, recently reported an EPS miss (‑$0.34 vs. $0.02 expected) despite revenue beating estimates, and carries a consensus analyst rating of Hold with a $5.38 price target.

Tudor Investment Corp ET AL bought a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 249,812 shares of the company's stock, valued at approximately $867,000. Tudor Investment Corp ET AL owned approximately 0.20% of Cytek Biosciences as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Royce & Associates LP grew its position in Cytek Biosciences by 26.9% during the third quarter. Royce & Associates LP now owns 1,763,262 shares of the company's stock worth $6,119,000 after buying an additional 373,456 shares in the last quarter. Topline Capital Management LLC grew its position in Cytek Biosciences by 32.7% during the third quarter. Topline Capital Management LLC now owns 6,944,280 shares of the company's stock worth $24,097,000 after buying an additional 1,713,020 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Cytek Biosciences by 237.3% during the second quarter. Squarepoint Ops LLC now owns 145,051 shares of the company's stock valued at $493,000 after purchasing an additional 102,047 shares in the last quarter. Cerity Partners LLC acquired a new stake in Cytek Biosciences during the second quarter valued at approximately $175,000. Finally, Quantbot Technologies LP boosted its holdings in Cytek Biosciences by 37.1% during the third quarter. Quantbot Technologies LP now owns 33,907 shares of the company's stock valued at $118,000 after purchasing an additional 9,176 shares in the last quarter. 69.46% of the stock is owned by institutional investors and hedge funds.

Cytek Biosciences Price Performance

Shares of CTKB opened at $4.62 on Wednesday. The company has a market capitalization of $590.71 million, a P/E ratio of -9.06 and a beta of 1.28. Cytek Biosciences, Inc. has a one year low of $2.37 and a one year high of $6.18. The business's 50 day simple moving average is $4.41 and its 200-day simple moving average is $4.67.

Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.36). The business had revenue of $62.14 million during the quarter, compared to analyst estimates of $58.80 million. Cytek Biosciences had a negative return on equity of 7.70% and a negative net margin of 33.02%. On average, sell-side analysts anticipate that Cytek Biosciences, Inc. will post -0.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CTKB has been the topic of a number of recent research reports. TD Cowen reaffirmed a "buy" rating on shares of Cytek Biosciences in a report on Thursday, January 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cytek Biosciences in a report on Friday, March 27th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Cytek Biosciences presently has a consensus rating of "Hold" and a consensus price target of $5.38.

Cytek Biosciences Profile

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company's core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.

Want to see what other hedge funds are holding CTKB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.